• 1
    Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol. Rev. 2013; 93: 32758.
  • 2
    Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics: 2011 update. A report from the American Heart Association. Circulation 2011; 123: e18209.
  • 3
    Fassa AA, Urban P. Stents and antiplatelet therapy. Adv. Cardiol. 2012; 47: 11424.
  • 4
    Renda G, de Caterina R. Impact of antiplatelet therapy in heart disease. Adv. Cardiol. 2012; 47: 519.
  • 5
    Reinhart KM, White CM, Baker WL. Prasugrel: A critical comparison with clopidogrel. Pharmacotherapy 2009; 29: 144151.
  • 6
    Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 2009; 361: 104557.
  • 7
    Storey RF, Bliden KP, Patil SB et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the onset/offset study. J. Am. Coll. Cardiol. 2010; 56: 18593.
  • 8
    Serebruany VL. Viewpoint: Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel. Thromb. Haemost. 2012; 108: 10247.
  • 9
    Aradi D, Komocsi A, Vorobcsuk A, Serebruany VL. Impact of clopidogrel and potent P2Y12-inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention. A systematic review and meta-analysis. Thromb. Haemost. 2013; 109: 93101.
  • 10
    Varenhorst C, Alstrom U, Scirica BM et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J. Am. Coll. Cardiol. 2012; 60: 162330.
  • 11
    Dinicolantonio JJ, Serebruany VL. Exploring the reduction in myocardial infarctions in the PLATO trial: Which patients benefited on ticagrelor vs. clopidogrel? Int. J. Cardiol. 2013; 165: 39639.
  • 12
    Serebruany VL. Adenosine release: A potential explanation for the benefits of ticagrelor in the platelet inhibition and clinical outcomes trial? Am. Heart J. 2011; 161: 14.
  • 13
    Huber K, Hamad B, Kirkpatrick P. Fresh from the pipeline. Ticagrelor. Nat. Rev. Drug Discov. 2011; 10: 2556.
  • 14
    James S, Budaj A, Aylward P et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: Results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation 2010; 122: 105667.
  • 15
    Saucedo JF. Antiplatelet therapy for patients with diabetes mellitus and acute coronary syndrome. Prim. Care Diabetes 2012; 6: 16777.
  • 16
    Flierl U, Schopp C, Jaitner J, Bauersachs J, Schafer A. The novel P2Y12 antagonist azd6140 rapidly and reversibly reduces platelet activation in diabetic rats. Thromb. Res. 2010; 125: e939.
  • 17
    Garrard J. Health Sciences Literature Review Made Easy: The Matrix Method, 3rd edn. Jones and Bartlett Learning, Sudbury. 2011.
  • 18
    Ramaraj R, Movahed MR, Hashemzadeh M. Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome. J. Interv. Cardiol. 2011; 24: 199207.
  • 19
    Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. Eur. J. Clin. Pharmacol. 2010; 66: 48796.
  • 20
    Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist azd6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur. Heart J. 2006; 27: 103847.
  • 21
    Davies SL. Ticagrelor. Drugs Today 2010; 46: 24350.
  • 22
    van Giezen JJJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Haemost. 2005; 31: 195204.
  • 23
    van Giezen JJJ, Berntsson P, Zachrisson H et al. Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thromb. Res. 2009; 124: 56571.
  • 24
    Alexopoulos D, Galati A, Xanthopoulou I et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: A pharmacodynamic study. J. Am. Coll. Cardiol. 2012; 60: 1939.
  • 25
    Teng A, Mitchell P, Butler K. Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals. Eur. J. Clin. Pharmacol. 2012; 68: 117582.
  • 26
    Parodi G, Valenti R, Bellandi B et al. Comparison of prasugrel and ticagrelor loading doses in STEMI patients: The rapid activity of platelet inhibitor drugs (RAPID) primary PCI study. J. Am. Coll. Cardiol. 2013; 61: 16016.
  • 27
    Cannon CP, Husted S, Harrington RA et al. Safety, tolerability, and initial efficacy of azd6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. J. Am. Coll. Cardiol. 2007; 50: 184451.
  • 28
    Storey RF, Thornton SM, Lawrance R et al. Ticagrelor yields consistent dose-dependent inhibition of adp-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets 2009; 20: 3418.
  • 29
    Jang J, Cho K, Jin H et al. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am. J. Cardiol. 2012; 110: 5028.
  • 30
    Serebruany VL. Viewpoint: Paradoxical excess mortality in the plato trial should be independently verified. Thromb. Haemost. 2011; 105: 7529.
  • 31
    Ohman EM, Roe MT. Explaining the unexpected: Insights from the platelet inhibition and clinical outcomes (PLATO) trial comparing ticagrelor and clopidogrel Editorial on Serebruany ‘Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified’(Thromb. Haemost. 2011; 105: 5). Thromb. Haemost. 2011; 105: 7635.
  • 32
    Wallentin L, Becker RC, James SK, Harrington RA. The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany ‘Viewpoint: Paradoxical excess mortality in the plato trial should be independently verified’. Thromb. Haemost. 2011; 105: 7602.
  • 33
    Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The onset/offset study. Circulation 2009; 120: 257785.
  • 34
    Gurbel PA, Bliden KP, Butler K et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The respond study. Circulation 2010; 121: 118899.
  • 35
    Gerczuk PZ, Kloner RA. An update on cardioprotection: A review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J. Am. Coll. Cardiol. 2012; 59: 96978.
  • 36
    Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J. Am. Coll. Cardiol. 2013; 61: 7237.
  • 37
    Scirica BM, Cannon CP, Emanuelsson H et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (platelet inhibition and patient outcomes) trial: Results of the continuous electrocardiographic assessment substudy. J. Am. Coll. Cardiol. 2011; 57: 190816.
  • 38
    Sleight P. Debate: Subgroup analyses in clinical trials. Fun to look at: But don't believe them!. Curr. Control Trials Cardiovasc. Med. 2000; 1: 257.